Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.37 |
| ▸ | ACVR2A | P27037 | 6/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 5/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22867010 | 0.90 | ACVR2A (0.39) | NLRP3ACVR2ATGFBR1GRM5DYRK1A | |
| SCHEMBL22866864 | 0.83 | PTGDR2 (0.45) | NLRP3ACVR2ATGFBR2PDE3BPDE3A | |
| SCHEMBL22867141 | 0.78 | NLRP3 (0.41) | NLRP3ACVR2ATGFBR1TGFBR2PDE3B | |
| SCHEMBL22867175 | 0.73 | NLRP3 (0.52) | NLRP3 | |
| SCHEMBL22867162 | 0.72 | NLRP3 (0.54) | NLRP3 | |
| SCHEMBL22867009 | 0.70 | NLRP3 (0.36) | NLRP3GABRA1 | |
| SCHEMBL21646547 | 0.68 | NLRP3 (0.51) | NLRP3ACVR2ATGFBR1GRM5DYRK1A | |
| SCHEMBL23762686 | 0.66 | NLRP3 (0.43) | NLRP3ACVR2ADYRK1ATGFBR2GABRA1 | |
| SCHEMBL22867129 | 0.66 | NLRP3 (0.53) | NLRP3ACVR2ATGFBR1GRM5DYRK1A | |
| SCHEMBL23063288 | 0.65 | MAPK13 (0.42) | ACVR2ATGFBR1DYRK1ATGFBR2MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002274-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | NLRP3 1/4885ACVR2A 4296/4885TGFBR1 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.